AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Eisai Co., Ltd., a Japanese pharmaceutical company headquartered in Tokyo, Japan, is set to roll out its novel, Leqembi, developed to treat Alzheimer's disease. The company is expected to give the first doses to 1,500 patients in China on the launch of this new medical product.
Growth Prediction After Leqembi's Release
According to Reuters, Eisai will also experience massive growth once the Leqembi officially hits the market. The new drug for Alzheimer's disease will first be available for Chinese patients later this year.
The pharma company's spokesperson explained that it anticipates growth to speed up even more in 2025 because the disease's diagnosis also changes. Moreover, the representative said that more suitable Alzheimer's blood tests will also be ready, and this will further help the company reach a more significant share of the Chinese market, where an estimated 17 million people were diagnosed with an early stage of Alzheimer's.
"China is one of the fastest-aging countries in the world and is one of the most important countries in the area of Alzheimer's disease for Eisai," Eisai's spokesman stated. "The potential growth for Leqembi in China is huge."
Price and Eligibility
Eisai plans to release Leqembi in China and sell it for 200,000 yuan or around $28,180 annually. The company said it has not yet decided if it will ask for government coverage and will only do so after assessing the demand in the private market. If Eisai pushes through, it will be included on China's National Reimbursement Drug List, and prices could be reduced.
To be eligible for treatment with Eisai's Leqembi, patients must undergo cognitive and genetic testing to determine whether they have a gene that increases the drug's adverse side effects.
They must also go through testing to see if they have abnormal levels of amyloid. Once the treatment begins, all patients will still undergo a series of MRI scans to detect any potential fatal swelling and bleeding in the brain.
Approval of LEQEMBI By the FDA
The FDA approved Eisai's Leqembi in July 2023 to treat Alzheimer's Disease. According to the press release, it is the first and only approved treatment that has been able to lessen the rate of the disease's progression. The drug can also slow down cognitive and functional decline in adult patients.
Photo by: Eisai Website
